Transforming Your Capabilities.
We provide the seamless integration of GI research into your practice to broaden your offerings, enhance care for your patients, and increase your support for referring physicians.
Transforming Your Research.
With premier integrated research partnerships across the country, we can offer a program supported by embedded study teams, leading to greater patient access at the point of care.
Transforming Your Outlook.
We are studying NASH and other diseases with the aim of developing new therapies to address growing problems and improve your overall health.
Let’s work together.
We’re taking on NASH with strong research partnerships and innovative approaches that leverage a proven platform. You can be part of it.
Hydrogel pill for overweight or obese patients approved by FDA.
In 2019, the FDA approved the Gelesis100 oral hydrogel pill therapy for weight management. This capsule induces a feeling of fullness to help patients control their hunger without the drawback of added calories. Read more about this first-of-its-kind hydrogel pill therapy.
ObjectiveGI Secures Series A Funding Led by Frist Cressey Ventures
Contacts:Colleen Hoke, ObjectiveGI email@example.comJillian Hammell, Crowley Webbjillian.firstname.lastname@example.org x237 ObjectiveGI Secures Series A Funding Led by Frist Cressey Ventures The clinically integrated ancillary care platform will accelerate expansion into local gastroenterology (GI) practices to provide specialized care for the rising NonAlcoholic SteatoHepatitis (NASH) epidemic NASHVILLE, TN, December 20, 2019 – ObjectiveGI, the integrated research and technology services platform company, announced today ...
A study from UT Southwestern identifies a protein in the gut linked to weight gain.
Dr. Lora Hooper and her colleagues found that the body’s metabolic rhythm is determined by gut bacteria: microbes activate the protein histone deacetylase 3 (HDAC3), which then interacts with the body’s metabolism to adjust fat absorption. The more fat consumed, the more HDAC3 tells the body to absorb this fat, which can lead to obesity.
MIT researchers recommend a new conceptual framework for stool donor selection.
To decrease the number of false-negative outcomes in fecal microbiota transplantation (FMT) trials, Dr. Eric J. Alm and colleagues propose a more rational approach for selection strategies.